Introduction
Self-monitoring of blood glucose levels is becoming an accepted and valuable advance in the management of diabetes.1-4 Although not suitable for every insulin-dependent patient, the technique offers the possibility of better and safer control of diabetes, shows the limitations of urine tests, and for the first time gives diabetics the information they need to take an active part in controlling their condition. Although the patient has to obtain a drop of capillary blood by needle or lancet, most patients prefer it to urine testing. ' Some patients have already bought their own monitors and others are being encouraged to do so. But, with four products available in the United Kingdom, their problem is in deciding which one to buy. In attempting to pick a "best buy" we assessed the four available monitors in three ways: by analysing the opinions of 24 patients, by comparing the performance of the units under field and laboratory conditions, and by seeking the opinion of an electronics engineer.
Patients and methods
The 24 insulin-dependent patients who tested the monitors comprised 12 men and 12 women aged 16 to 60 years (mean 35) who had had diabetes for 3 months to 35 years (mean 10). One patient had had experience of self-monitoring with an Eyetone machine and one with a Glucochek. One patient was partially sighted but could test urine with Clinitest tablets and administer insulin with a Click-count syringe. Our own experience consisted of five years of using the Eyetone and a few weeks with Glucochek. Initially 24 new monitors werebought six Glucochek machines, but they had not been used. (During the trial period two further Glucochek monitors were included.)
With all of the machines the patient places a drop of blood on an enzyme-impregnated reagent strip (Dextrostix or Reflotest) and removes it after one minute. The colour change, dependent on the glucose content of the blood, is determined by the reflectance of light in the previously calibrated monitor.
After a seven-day practice period each patient used each type of monitor for two weeks. Patients performed at least two tests a day, and they were encouraged to take the monitors with them to work or while travelling. Each week they attended our unit, where a venous blood sample was taken by a doctor or nurse. We then observed the patients while they tested part of the sample with the monitor they were assessing. The rest of the sample was analysed by Technicon autoanalyser in our biochemistry department. The patient's technique was thus checked and correlations of blood glucose me4surement between each monitor type and the autoanalyser were made on the basis of two correlations per monitor per patient. The patients were not told the laboratory results. At the end of each fortnight the patient changed to a different type of monitor. At the end of the eight weeks each patient completed a detailed questionnaire and assessed various features of each machine on a four-star scale. All 26 monitors were then tested in the laboratory. The built-in timers on the Glucochek and Hypocount monitors were checked against a stopwatch. Tests of linearity were made using tech-chek (a set of calibration solutions of known values 2 5, 5 0, 7 2, and 13 9 mmol/l supplied by Ames) or with freshly drawn blood samples. Reproducibility tests were made with fresh blood samples of known glucose content tested at least five times on each monitor.
One of each of the four types of monitor was examined by our area health authority electronics engineer. He assessed their conformity with DHSS requirements where applicable (Hospital Technical Memorandum No 8), but did no electronic or durability tests. Table I shows the basic data on the four monitors. We understand from Medistron Ltd that it has now modified the Glucochek timer so that the timer does not have to be warmed up before producing a consistent timing of 60 seconds. All new Glucochek monitors have been modified, and since 20 September Medistron have recommended that this modification be carried out on all the earlier units sold (up to serial number 2100). Medistron also said that some early monitors had too high a setting for the low-battery-state warning light.
Although the calibration of the two battery-operated models is preset by the manufacturer, we and most of our patients think that some form of calibration check across the range should be available to the patient, who will otherwise have no means of recognising a malfunction unless it be gross.
Between the two mains-operated monitors, the division of patient opinion was much closer, with the Reflomat marginally more popular. The Reflomat performed with the best reproducibility. The present Reflotest glucose system does not read accurately below 3 0 mmol/l but a modification of the test strip (Reflotest Hypoglycemie) is available to cover the range 0-55 to 8-3 mmol/l. When cost was not being considered one patient gave Reflomat as overall first choice. The greater difficulty in 4 Histamine is a non-specific bronchoconstrictor in increased bronchial lability.8 9 It is useful in assessing the protective effect of drugs, since the bronchoconstriction can be controlled and its effect is transient.'0 We decided to assess the protective effect of a single dose of salbutamol powder using inhaled histamine. The trial was approved by the local ethical committee.
Subjects and methods
Twelve children aged 6-13 years with episodic asthma were studied. All could perform satisfactory forced expiratory manoeuvres. Eleven had a baseline FEV, of 70% or more of the predicted normal value on each day (normal values taken from Cogswell et all'). One boy had an FEV, of 58% predicted on one day and between 70', and 90% on the other days. Only steroids were continued from 12 hours before the start of each study day until after the last histamine challenge of that day.
Histamine challenge-The histamine challenge procedure used was similar to that of Chai et al.'2 FEV, was recorded on a Vitalograph.
When consistent results were obtained the best of three was used as a baseline. Buffered histamine acid phosphate was used in roughly doubling concentrations from 0 03 mg/ml to 10 mg/ml. Solutions were administered by facemask from a Bard Mini-Neb nebuliser driven by oxygen at 8 I/min. Five inspiratory capacity breaths were taken first of diluent alone, and three minutes later the FEV, was recorded. Provided there was no fall in FEV, with the diluent this was repeated with increasing concentrations of histamine at fourminute intervals until the FEV, had fallen by 20% or more. The test was then stopped. The concentration of histamine that would produce a 20% fall (provocation concentration 20; PC20) was calculated from the dose-response curve. If the FEV, did not fall by 20% with the top concentration (10 mg/ml) a PC20 was calculated by extrapolation up to 20 mg/ml, but not beyond.
